In adults with advanced-stage Hodgkin’s lymphoma, the CD30-directed antibody–drug conjugate brentuximab vedotin combined with multiagent chemotherapy has been shown to have greater efficacy ...

Hodgkin's lymphoma and anaplastic large-cell lymphoma are the two most common tumors expressing CD30. Previous attempts to target the CD30 antigen with monoclonal-based therapies have shown ...

Brentuximab vedotin (Adcetris, Seattle Genetics) is a chimeric CD30 antibody conjugated to approximately four molecules of monomethyl auristatin E (MMAE) with a cleavable dipeptide linker.

Novel combination of acimtamig and an allogenic natural killer cell product shows safety and promising objective response ...

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma. New England Journal of Medicine , 2022; DOI: 10.1056/NEJMoa2206125 Cite This Page : ...

Please provide your email address to receive an email when new articles are posted on . The replacement of vincristine with brentuximab vedotin in standard front-line treatment appeared safe and ...

Brentuximab vedotin (Adcetris) in combination with nivolumab (Opdivo) after autologous hematopoietic stem-cell transplantation (HSCT) resulted in improved outcomes in patients with high-risk ...

SAN DIEGO — For patients with CD30 expressing cutaneous T cell lymphoma (CTCL), treatment with the CD30 targeting antibody brentuximab vedotin (Adcetris, Seattle Genetics) was superior to ...

--(BUSINESS WIRE)-- Seagen Inc. (NASDAQ: SGEN) today announced that 12- and 24-month progression free survival data will be presented for an ADCETRIS® (brentuximab vedotin) and immunotherapy ...

Dr. Ansell and his colleagues also evaluated long-term toxicities of brentuximab vedotin. They found that neuropathy from the addition of the drug to treatment was found to resolve over time. In ...

Overall survival was significantly improved in patients treated with brentuximab vedotin plus lenalidomide/rituximab compared with placebo plus lenalidomide/rituximab ...

Nivolumab outperformed the drug brentuximab vedotin (Adcetris), extending progression-free survival by 94% at one year compared to 86%, said lead researcher Dr. Alex Herrera, a hematologist ...